OptimizeRx Corporation OPRX
9.67 USD +0.32 (+3.42%)
Nov 11, 2026, 2:06 PM EST
9.40 Day range 9.83
4.54 52-week range 16.37
- YTD
- -21.13%
- 1 year
- -39.14%
News
benzinga.com B. Riley Securities Maintains Buy on OptimizeRx, Raises Price Target to $11 B. Riley Securities analyst Anderson Schock maintains OptimizeRx (NASDAQ:OPRX) with a Buy and raises the price target from $10 to $11.
benzinga.com Citizens Maintains Market Outperform on OptimizeRx, Raises Price Target to $11 Citizens analyst Constantine Davides maintains OptimizeRx (NASDAQ:OPRX) with a Market Outperform and raises the price target from $9 to $11.
benzinga.com OptimizeRx Affirms FY2026 Sales Guidance of $95.000M-$100.000M vs $97.427M Est OptimizeRx (NASDAQ:OPRX) affirms FY2026 sales outlook from $95.000 million-$100.000 million to $95.000 million-$100.000 million vs $97.427 million estimate.
benzinga.com OptimizeRx Q2 Adj. EPS $0.16 Beats $0.12 Estimate, Sales $20.504M Beat $20.204M Estimate OptimizeRx (NASDAQ:OPRX) reported quarterly earnings of $0.16 per share which beat the analyst consensus estimate of $0.12 by 33.33 percent. This is a 33.33 percent decrease over earnings of $0.24…
benzinga.com OptimizeRx Rolls Out CopayCue To Provide Enhanced Brand Savings For Physicians OptimizeRx Corp. (the "Company") (Nasdaq: OPRX), a leading provider of healthcare technology solutions helping life sciences companies reach and engage healthcare professionals (HCPs) and patients at…- benzinga.com OptimizeRx's Electronic Health Record Network Integrated By DeepIntent OptimizeRx Corp. (NASDAQ:OPRX), a leading provider of healthcare technology solutions helping life sciences companies reach and engage healthcare providers (HCPs) and patients at the most important…
- benzinga.com Lake Street Maintains Buy on OptimizeRx, Lowers Price Target to $11 Lake Street analyst Eric Martinuzzi maintains OptimizeRx (NASDAQ:OPRX) with a Buy and lowers the price target from $20 to $11.
benzinga.com B. Riley Securities Maintains Buy on OptimizeRx, Lowers Price Target to $10 B. Riley Securities analyst Anderson Schock maintains OptimizeRx (NASDAQ:OPRX) with a Buy and lowers the price target from $11 to $10.
benzinga.com 12 Health Care Stocks Moving In Wednesday's Intraday Session - benzinga.com Stephens & Co. Maintains Equal-Weight on OptimizeRx, Lowers Price Target to $7 Stephens & Co. analyst Jeff Garro maintains OptimizeRx (NASDAQ:OPRX) with a Equal-Weight and lowers the price target from $10 to $7.
- benzinga.com Stifel Maintains Buy on OptimizeRx, Lowers Price Target to $14 Stifel analyst David Grossman maintains OptimizeRx (NASDAQ:OPRX) with a Buy and lowers the price target from $17 to $14.
- benzinga.com OptimizeRx Reports Q1 2026 Results: Full Earnings Call Transcript
benzinga.com 12 Health Care Stocks Moving In Tuesday's After-Market Session 
benzinga.com OptimizeRx Lowers FY2026 Sales Guidance from $109.000M-$114.000M to $95.000M-$100.000M vs $111.438M Est OptimizeRx (NASDAQ:OPRX) lowers FY2026 sales outlook from $109.000 million-$114.000 million to $95.000 million-$100.000 million vs $111.438 million estimate.- benzinga.com OptimizeRx Q1 Adj. EPS $0.14 Beats $0.00 Estimate, Sales $19.844M Beat $18.353M Estimate OptimizeRx (NASDAQ:OPRX) reported quarterly earnings of $0.14 per share which beat the analyst consensus estimate of $0.00 by Infinity percent. This is a 75 percent increase over earnings of $0.08…
benzinga.com Earnings Scheduled For May 12, 2026 - benzinga.com OptimizeRx Launches New Programmatic Connection Point Between OptimizeRx's Proprietary EHR Network And DSPs OptimizeRx Corp. (the "Company") (NASDAQ:OPRX), a leading provider of healthcare technology solutions helping life sciences companies reach and engage healthcare providers (HCPs) and patients at the…
benzinga.com 12 Health Care Stocks Moving In Wednesday's Pre-Market Session - benzinga.com Lake Street Maintains Buy on OptimizeRx, Lowers Price Target to $20 Lake Street analyst Eric Martinuzzi maintains OptimizeRx (NASDAQ:OPRX) with a Buy and lowers the price target from $24 to $20.
benzinga.com OptimizeRx Warns Of Volatility From 'Most Favored Nation' Pricing Uncertainty OptimizeRx CEO warns of increased market volatility and uncertainty around MFN pricing. Lower 2026 forecasts due to cautious spending.
benzinga.com Assessing OptimizeRx: Insights From 4 Financial Analysts 
benzinga.com Roth Capital Maintains Buy on OptimizeRx, Lowers Price Target to $18 Roth Capital analyst Richard Baldry maintains OptimizeRx (NASDAQ:OPRX) with a Buy and lowers the price target from $32 to $18.
benzinga.com 12 Health Care Stocks Moving In Friday's Intraday Session - benzinga.com B. Riley Securities Reiterates Buy on OptimizeRx, Lowers Price Target to $11 B. Riley Securities analyst Anderson Schock reiterates OptimizeRx (NASDAQ:OPRX) with a Buy and lowers the price target from $28 to $11.
- benzinga.com Stephens & Co. Maintains Equal-Weight on OptimizeRx, Lowers Price Target to $10 Stephens & Co. analyst Jeff Garro maintains OptimizeRx (NASDAQ:OPRX) with a Equal-Weight and lowers the price target from $17 to $10.
- benzinga.com Stifel Maintains Buy on OptimizeRx, Lowers Price Target to $17 Stifel analyst David Grossman maintains OptimizeRx (NASDAQ:OPRX) with a Buy and lowers the price target from $21 to $17.
- benzinga.com 12 Health Care Stocks Moving In Thursday's After-Market Session
benzinga.com OptimizeRx Lowers FY2026 Sales Guidance from $118.000M-$124.000M to $109.000M-$114.000M OptimizeRx (NASDAQ:OPRX) lowers FY2026 sales outlook from $118.000 million-$124.000 million to $109.000 million-$114.000 million.- benzinga.com OptimizeRx Q4 Adj. EPS $0.51 Beats $0.23 Estimate, Sales $32.200M Beat $31.100M Estimate OptimizeRx (NASDAQ:OPRX) reported quarterly earnings of $0.51 per share which beat the analyst consensus estimate of $0.23 by 124.67 percent. This is a 70 percent increase over earnings of $0.30 per…
- benzinga.com Earnings Scheduled For March 5, 2026
- benzinga.com OptimizeRx Announced Four New Partner Agreements That Expand Its In-Workflow Point-of-care Network, Fortify Its Long-term Competitive Position, And Increase Total National Provider Identifier Reach, Deal Terms Were Undisclosed The newly executed agreements include:An exclusive, multi-year agreement with a high-demand e-prescribing (eRx) platform previously available only through a competitive networkA new partnership that…
- benzinga.com 12 Health Care Stocks Moving In Thursday's After-Market Session
benzinga.com Earnings Scheduled For November 6, 2025 - benzinga.com OptimizeRx Partners With Lamar Advertising To Revolutionize OOH Advertising For Pharmaceutical And Healthcare Brands Strategic Partnership Combines OptimizeRx's Patented Micro-Neighborhood® Targeting Data with Lamar's Vast Nationwide OOH Network to Strengthen OOH Media for Healthcare MarketingWALTHAM, Mass., Sept.…
- benzinga.com 12 Health Care Stocks Moving In Friday's Intraday Session
- benzinga.com 12 Health Care Stocks Moving In Friday's Pre-Market Session
benzinga.com Why Expedia Shares Are Trading Higher By Around 18%; Here Are 20 Stocks Moving Premarket - benzinga.com 12 Health Care Stocks Moving In Thursday's After-Market Session
- benzinga.com Earnings Scheduled For August 7, 2025
- benzinga.com 12 Health Care Stocks Moving In Tuesday's After-Market Session
- benzinga.com Market-Moving News for May 13th COIN: 10% | Coinbase Global shares are trading higher it was announced that the company will join the S&P 500, effective before the opening of trading on Monday, May 19. OPRX: 24% | OptimizeRx shares
- benzinga.com 12 Health Care Stocks Moving In Monday's After-Market Session
- benzinga.com Earnings Scheduled For May 12, 2025
- benzinga.com 12 Health Care Stocks Moving In Wednesday's Intraday Session
- benzinga.com Earnings Scheduled For March 12, 2025
- benzinga.com 12 Health Care Stocks Moving In Thursday's Pre-Market Session
- benzinga.com Earnings Scheduled For November 13, 2024
- benzinga.com 12 Health Care Stocks Moving In Wednesday's Intraday Session
- benzinga.com Gold Rises Over 1%; Arcos Dorados Shares Fall After Q1 Results
- benzinga.com Why Bolt Biotherapeutics Shares Are Trading Lower By Around 34%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session